Sonnet releases virtual investor "what this means" segment

- dr. richard kenney, chief medical officer of sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (proc) (sb221)
SONN Ratings Summary
SONN Quant Ranking